Veru (NASDAQ:VERU – Get Free Report) and Lotus Pharmaceuticals (OTCMKTS:LTUS – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
Volatility and Risk
Veru has a beta of -0.48, indicating that its stock price is 148% less volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of -0.42, indicating that its stock price is 142% less volatile than the S&P 500.
Profitability
This table compares Veru and Lotus Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Veru | -376.38% | -115.99% | -66.94% |
Lotus Pharmaceuticals | N/A | N/A | N/A |
Institutional and Insider Ownership
Valuation & Earnings
This table compares Veru and Lotus Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Veru | $16.30 million | 7.42 | -$93.15 million | ($0.34) | -2.43 |
Lotus Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
Lotus Pharmaceuticals has lower revenue, but higher earnings than Veru.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Veru and Lotus Pharmaceuticals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Veru | 0 | 0 | 4 | 0 | 3.00 |
Lotus Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Veru currently has a consensus price target of $4.00, suggesting a potential upside of 384.20%. Given Veru’s higher probable upside, research analysts clearly believe Veru is more favorable than Lotus Pharmaceuticals.
Summary
Veru beats Lotus Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
About Veru
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
About Lotus Pharmaceuticals
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.